Categories: BionicHealthcareNews

LIAN Group Expands Healthcare Platform with Strategic Acquisition of Scientis, #1 Dermatologist-Recommended Solution for Hyperpigmentation

GENEVA, Aug. 27, 2024 /PRNewswire/ — As part of their Healthcare investment platform, LIAN Group, an innovative investor and operator known for its healthcare investment in the #1 Swiss dentistry network, Cheeze, announces the acquisition of Scientis, a pioneering Swiss Cosmeceutical company. This acquisition strengthens LIAN’s healthcare footprint, as part of their cross-industry investments, focusing on leading solutions that address evolving needs.

Scientis is a Swiss dermatology company dedicated to skin pigmentation with its flagship product Cyspera®. The Cyspera® product line, contains proprietary Cysteamine Isobionic-Amide Complex™ , clinically proven as a pigment corrector. Its unique formula featuring powerful antioxidant properties, positions Cyspera as the first topical product to harness these benefits for uneven skin tone and discoloration. This unique proposition positions the company for global market penetration, with a strong presence already established in Asia and the US.

“We are thrilled to welcome Scientis to LIAN Group’s healthcare platform. We are committed to accelerating Scientis’ growth and sales in new markets by leveraging our network, expertise and resources to expand into new markets, streamline operations, develop innovative products and services, and empower patients and healthcare professionals with high-quality solutions.” says Fiorenzo Manganiello, Managing Partner of LIAN Group.

This acquisition signifies LIAN Group’s commitment to expanding its healthcare platform beyond dentistry as they plan for further acquisitions in the beauty and wellbeing sectors. The LIAN core team will work with Scientis to unlock new markets, optimize operations, and develop new offerings that benefit both patients and healthcare professionals.

About: LIAN Group is a diversified holding group with an “owner and operator” model, fostering innovation and growth across three core platforms: Healthcare, Crypto/Blockchain and AI/Digital Infrastructure. They operate through two models: Venture Studio and Direct Investment, focusing on strategic deals that align with their vision.

Logo – https://healthtechnologynet.com/wp-content/uploads/2024/08/LIAN_Group_Logo.jpg

Media Contact: Erenik Yzeiraj; +41787995758; ey@liangroup.io 

View original content to download multimedia:https://www.prnewswire.com/news-releases/lian-group-expands-healthcare-platform-with-strategic-acquisition-of-scientis-1-dermatologist-recommended-solution-for-hyperpigmentation-302229617.html

SOURCE LIAN Group

Staff

Recent Posts

Largest Virginia FQHC Leverages eClinicalWorks and Sunoh.ai to Witness Significant Time-Savings and Reduced Physician Burnout

eClinicalWorks and the AI medical scribe assist the 126-provider health center in completing documentation at…

6 minutes ago

The New Clinically Integrated Network of Indiana Launches to Improve Access, Quality, and Affordability of Healthcare Statewide

INDIANAPOLIS, Nov. 22, 2024 /PRNewswire/ -- Health centers across the state of Indiana have joined…

9 minutes ago

International Genomics Conference (ICG-19) Opens at BGI Group HQ in Shenzhen

SHENZHEN, China, Nov. 22, 2024 /PRNewswire/ -- The 19th Annual Meeting of the International Conference…

9 minutes ago

MIT Sloan Professor Steven Eppinger Joins SurgiBox’s Board of Directors

CAMBRIDGE, Mass., Nov. 22, 2024 /PRNewswire/ -- SurgiBox, a pioneer in ultra-portable, inflatable surgical environments…

9 minutes ago

Legal Notice Regarding ESHA Data Security Incident

FORT WORTH, Texas, Nov. 22, 2024 /PRNewswire/ -- ESHA, Inc ("ESHA") provide certain revenue cycle…

9 minutes ago